NH1,902.90

Narayana Hrudayalaya Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISNEULANDLABNATCOPHARMLALPATHLABSAILIFECOHANCEMcap ₹38,888 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
NH
FY26
APOLLOHOSP
FY26
MAXHEALTH
FY26
FORTIS
FY26
Peer
Median
Valuation — at last close
P/E47.97×65.86×69.66×65.36×65.86× -27%
P/B8.57×12.82×9.36×6.70×9.36× -8%
EV/EBITDA26.33×34.95×46.08×33.84×34.95× -25%
Market Cap₹38,888 Cr₹1.28L Cr₹1.01L Cr₹68,097 Cr₹1.01L Cr -61%
Growth
Revenue CAGR 3Y20.39%14.94%22.43%13.17%14.94% +36%
Revenue CAGR 5Y25.05%19.03%27.30%17.76%19.03% +32%
Net Income CAGR 3Y9.94%33.35%9.34%18.91%18.91% -47%
Revenue YoY (latest Q)78.05%20.56%16.70%17.46%17.46% +347%
Net Income YoY (latest Q)5.37%38.41%4.87%2.26%4.87% +10%
Profitability
EBITDA Margin20.47%14.94%26.79%22.84%22.84% -10%
Net Income Margin10.21%7.94%17.23%11.66%11.66% -12%
Return on Common Equity17.75%19.47%13.42%10.25%13.42% +32%
Return on Capital Employed10.98%18.41%11.94%11.81%11.94% -8%
Return on Assets6.46%9.02%8.37%6.67%8.37% -23%
Credit & Quality
Total Debt/Equity1.07×0.57×0.32×0.28×0.32× +234%
Interest Coverage4.80×6.44×7.64×5.20×6.44× -25%
Scale — latest FY
Revenue / Total Income₹7,896 Cr₹25,229 Cr₹8,373 Cr₹9,128 Cr₹9,128 Cr -13%
Net Income₹806 Cr₹2,003 Cr₹1,442 Cr₹1,064 Cr₹1,442 Cr -44%
Total Assets₹12,474 Cr₹22,197 Cr₹17,231 Cr₹15,966 Cr₹17,231 Cr -28%
EPS₹39.67₹135.04₹14.83₹13.8₹14.83 +167%
Book Value per Share₹222.13₹693.64₹110.43₹134.69₹134.69 +65%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.